• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Simple and Rapid Diagnosis of Preeclampsia

This project aims to develop an early stage detection of preeclampsia that will be based on the Surface Enhanced Raman Scattering (SERS) Homogenous No-Wash (HNW) platform enabling detection of clinically validated biomarkers without pre-processing or washing from a complex sample in a point-of-care setting. Clinical performance will be assessed using non-invasive urine specimens and optimized assay algorithms to improve specificity for interventions recommended by the World Health Organization (WHO). SERS HNW is an innovative multiplex, low-cost, point-of-care SERS HNW test for prediction of preeclampsia risk. Most of the WHO ASSURED criteria are met using the Surface Enhanced Raman Scattering (SERS) Homogenous No-Wash (HNW) platform. SERS HNW provides ELISA-like analytical sensitivity, is low-cost (< $1.00 per test), semi-quantitative, requires minimal training, and has the ability to multiplex pathophysiological biomarkers. Multiplex capabilities in the platform provide the potential to detect maternal/antenatal disease beyond preeclampsia.

More information about Saving Lives at Birth (Round 4)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.